Inhibition of RIPK1 prevents keratinocyte cell death and reduces skin inflammation in type 1 mediated chronic inflammatory skin diseases

BACKGROUND: Type 1 mediated chronic inflammatory skin diseases (ISD) affect skin, hair, nails and mucosa and dramatically impact patient's quality of life. The two most prominent examples are lichen planus (LP) and cutaneous lupus erythematosus (CLE). Various cell death pathways are activated in both diseases, including apoptosis and necroptosis. RIPK1 is a key regulator of programmed cell death and thus represents a potential new target for the treatment of these diseases. OBJECTIVE: To determine the impact of RIPK1 on cell death and inflammation in LP and CLE. METHODS: RNA-sequencing of ISD (n=179). Assessing cell death, hypothermia and inflammatory markers affected by Eclitasertib, a novel RIPK1 inhibitor, in human cells, murine TNF-

• Jargosch, M.
• Wasserer, S.
• Eigemann, J.
• Raunegger, T.
• Kurzen, N.
• Ding-Pfennigdorff, D.
• Bartnik, E.
• Schmidt-Weber, C. B.
• Biedermann, T.
• Eyerich, S.
• Eyerich, K.
• Florian, P.
• Herrmann, M.
• Saas, J.
• Lauffer, F.